ID

19589

Beschrijving

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27; ODM derived from: https://clinicaltrials.gov/show/NCT00354302

Link

https://clinicaltrials.gov/show/NCT00354302

Trefwoorden

Versies (2)
  1. 12-01-17 12-01-17 -
  2. 02-09-21 02-09-21 -
Geüploaded op

12 januari 2017

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Breast Cancer NCT00354302

Engels

Eligibility Breast Cancer NCT00354302

1 Formulieren  
Criteria
Beschrijving

Criteria

enrolled in and meets eligibility requirements for protocol can-ncic-ma27
Beschrijving

Enrollment in clinical trial | Clinical Trial Eligibility Criteria Fulfill

Datatype

boolean

Alias
UMLS CUI [1]
C4041024
UMLS CUI [2,1]
C1516637
UMLS CUI [2,2]
C1550543
acceptable quality dual-energy x-ray absorptiometry (dexa) of the l1-l4 postero-anterior spine and hip within 12 weeks prior to randomization on protocol can-ncic-ma27
Beschrijving

Dual-Energy X-Ray Absorptiometry Lumbar spine Postero-Anterior | Dual-Energy X-Ray Absorptiometry Hip

Datatype

boolean

Alias
UMLS CUI [1,1]
C1510486
UMLS CUI [1,2]
C3887615
UMLS CUI [1,3]
C1996865
UMLS CUI [2,1]
C1510486
UMLS CUI [2,2]
C0019552
hormone receptor status:
Beschrijving

Hormone Receptor Status

Datatype

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
estrogen receptor- and/or progesterone receptor-positive tumor
Beschrijving

Estrogen receptor positive tumor | Progesterone receptor positive tumor

Datatype

boolean

Alias
UMLS CUI [1]
C1562312
UMLS CUI [2]
C1562928
patient characteristics:
Beschrijving

Client Characteristics

Datatype

boolean

Alias
UMLS CUI [1]
C0815172
female
Beschrijving

Gender

Datatype

boolean

Alias
UMLS CUI [1]
C0079399
postmenopausal
Beschrijving

Postmenopausal state

Datatype

boolean

Alias
UMLS CUI [1]
C0232970
no malabsorption syndrome
Beschrijving

Malabsorption Syndrome

Datatype

boolean

Alias
UMLS CUI [1]
C0024523
no known cholecalciferol (vitamin d) deficiency, active hyper- or hypoparathyroidism, or paget's disease
Beschrijving

Cholecalciferol Deficiency | Vitamin D Deficiency | Hyperparathyroidism | Hypoparathyroidism | Paget's Disease

Datatype

boolean

Alias
UMLS CUI [1,1]
C0008318
UMLS CUI [1,2]
C0011155
UMLS CUI [2]
C0042870
UMLS CUI [3]
C0020502
UMLS CUI [4]
C0020626
UMLS CUI [5]
C1368019
no uncontrolled thyroid disease, cushing's disease, or other pituitary disease
Beschrijving

Thyroid Disease Uncontrolled | Cushing Syndrome | Pituitary Disease

Datatype

boolean

Alias
UMLS CUI [1,1]
C0040128
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C0010481
UMLS CUI [3]
C0032002
no other bone disease (including osteomalacia or osteogenesis imperfecta)
Beschrijving

Bone Disease | Osteomalacia | Osteogenesis Imperfecta

Datatype

boolean

Alias
UMLS CUI [1]
C0005940
UMLS CUI [2]
C0029442
UMLS CUI [3]
C0029434
prior concurrent therapy:
Beschrijving

Therapeutic procedure

Datatype

boolean

Alias
UMLS CUI [1]
C0087111
more than 6 months since prior drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (stratum i)
Beschrijving

Pharmaceutical Preparations Prevention of osteoporosis | Investigational New Drugs Prevention of osteoporosis | Diphosphonates Prevention of osteoporosis

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C3650929
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C3650929
UMLS CUI [3,1]
C0012544
UMLS CUI [3,2]
C3650929
more than 12 months since prior and no concurrent anticonvulsants
Beschrijving

Anticonvulsants

Datatype

boolean

Alias
UMLS CUI [1]
C0003286
more than 6 months since prior and no concurrent corticosteroids at doses > 5 mg/day of prednisone (or equivalent) for > 2 weeks
Beschrijving

Adrenal Cortex Hormones Dose Daily | Prednisone Dose Daily | Prednisone Equivalent Dose Daily

Datatype

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0332173
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0332173
UMLS CUI [3,1]
C0032952
UMLS CUI [3,2]
C0205163
UMLS CUI [3,3]
C0178602
UMLS CUI [3,4]
C0332173
more than 12 months since prior and no concurrent anabolic steroids
Beschrijving

Anabolic steroids

Datatype

boolean

Alias
UMLS CUI [1]
C0002744
no prior bisphosphonates (stratum ii)
Beschrijving

Diphosphonates

Datatype

boolean

Alias
UMLS CUI [1]
C0012544
no concurrent sodium fluoride at daily doses ≥ 5 mg/day
Beschrijving

Sodium Fluoride Dose Daily

Datatype

boolean

Alias
UMLS CUI [1,1]
C0037508
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0332173
no long-term (i.e., > 6 months) use of coumarins
Beschrijving

Coumarins Long-term

Datatype

boolean

Alias
UMLS CUI [1,1]
C0010207
UMLS CUI [1,2]
C0443252
no concurrent drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (for patients with no osteopenia or osteoporosis [stratum i])
Beschrijving

Pharmaceutical Preparations Prevention of osteoporosis | Investigational New Drugs Prevention of osteoporosis | Diphosphonates Prevention of osteoporosis | Osteopenia | Osteoporosis

Datatype

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C3650929
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C3650929
UMLS CUI [3,1]
C0012544
UMLS CUI [3,2]
C3650929
UMLS CUI [4]
C0029453
UMLS CUI [5]
C0029456
Terug naar het begin van de pagina

Similar models

Eligibility Breast Cancer NCT00354302

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Enrollment in clinical trial | Clinical Trial Eligibility Criteria Fulfill
Item
enrolled in and meets eligibility requirements for protocol can-ncic-ma27
boolean
C4041024 (UMLS CUI [1])
C1516637 (UMLS CUI [2,1])
C1550543 (UMLS CUI [2,2])
Dual-Energy X-Ray Absorptiometry Lumbar spine Postero-Anterior | Dual-Energy X-Ray Absorptiometry Hip
Item
acceptable quality dual-energy x-ray absorptiometry (dexa) of the l1-l4 postero-anterior spine and hip within 12 weeks prior to randomization on protocol can-ncic-ma27
boolean
C1510486 (UMLS CUI [1,1])
C3887615 (UMLS CUI [1,2])
C1996865 (UMLS CUI [1,3])
C1510486 (UMLS CUI [2,1])
C0019552 (UMLS CUI [2,2])
Hormone Receptor Status
Item
hormone receptor status:
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Estrogen receptor positive tumor | Progesterone receptor positive tumor
Item
estrogen receptor- and/or progesterone receptor-positive tumor
boolean
C1562312 (UMLS CUI [1])
C1562928 (UMLS CUI [2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Postmenopausal state
Item
postmenopausal
boolean
C0232970 (UMLS CUI [1])
Malabsorption Syndrome
Item
no malabsorption syndrome
boolean
C0024523 (UMLS CUI [1])
Cholecalciferol Deficiency | Vitamin D Deficiency | Hyperparathyroidism | Hypoparathyroidism | Paget's Disease
Item
no known cholecalciferol (vitamin d) deficiency, active hyper- or hypoparathyroidism, or paget's disease
boolean
C0008318 (UMLS CUI [1,1])
C0011155 (UMLS CUI [1,2])
C0042870 (UMLS CUI [2])
C0020502 (UMLS CUI [3])
C0020626 (UMLS CUI [4])
C1368019 (UMLS CUI [5])
Thyroid Disease Uncontrolled | Cushing Syndrome | Pituitary Disease
Item
no uncontrolled thyroid disease, cushing's disease, or other pituitary disease
boolean
C0040128 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0010481 (UMLS CUI [2])
C0032002 (UMLS CUI [3])
Bone Disease | Osteomalacia | Osteogenesis Imperfecta
Item
no other bone disease (including osteomalacia or osteogenesis imperfecta)
boolean
C0005940 (UMLS CUI [1])
C0029442 (UMLS CUI [2])
C0029434 (UMLS CUI [3])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Pharmaceutical Preparations Prevention of osteoporosis | Investigational New Drugs Prevention of osteoporosis | Diphosphonates Prevention of osteoporosis
Item
more than 6 months since prior drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (stratum i)
boolean
C0013227 (UMLS CUI [1,1])
C3650929 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2,1])
C3650929 (UMLS CUI [2,2])
C0012544 (UMLS CUI [3,1])
C3650929 (UMLS CUI [3,2])
Anticonvulsants
Item
more than 12 months since prior and no concurrent anticonvulsants
boolean
C0003286 (UMLS CUI [1])
Adrenal Cortex Hormones Dose Daily | Prednisone Dose Daily | Prednisone Equivalent Dose Daily
Item
more than 6 months since prior and no concurrent corticosteroids at doses > 5 mg/day of prednisone (or equivalent) for > 2 weeks
boolean
C0001617 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
C0032952 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0332173 (UMLS CUI [2,3])
C0032952 (UMLS CUI [3,1])
C0205163 (UMLS CUI [3,2])
C0178602 (UMLS CUI [3,3])
C0332173 (UMLS CUI [3,4])
Anabolic steroids
Item
more than 12 months since prior and no concurrent anabolic steroids
boolean
C0002744 (UMLS CUI [1])
Diphosphonates
Item
no prior bisphosphonates (stratum ii)
boolean
C0012544 (UMLS CUI [1])
Sodium Fluoride Dose Daily
Item
no concurrent sodium fluoride at daily doses ≥ 5 mg/day
boolean
C0037508 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
Coumarins Long-term
Item
no long-term (i.e., > 6 months) use of coumarins
boolean
C0010207 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
Pharmaceutical Preparations Prevention of osteoporosis | Investigational New Drugs Prevention of osteoporosis | Diphosphonates Prevention of osteoporosis | Osteopenia | Osteoporosis
Item
no concurrent drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (for patients with no osteopenia or osteoporosis [stratum i])
boolean
C0013227 (UMLS CUI [1,1])
C3650929 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2,1])
C3650929 (UMLS CUI [2,2])
C0012544 (UMLS CUI [3,1])
C3650929 (UMLS CUI [3,2])
C0029453 (UMLS CUI [4])
C0029456 (UMLS CUI [5])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial